Financials
Financial year 2025
PharmaCross from Deinze, company number BE0888580475, closed financial year 2025 with a result of € 503,893 after tax. For that financial year PharmaCross recorded revenue of € 18.2 million and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 921,276 to € 503,893. The company is profitable. The buffer shrank hard: equity is 80 % below last year. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 11, 2026.
€ 1.2 million
▼ 80% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 503,893
▼ 45% vs 2024
Profit after tax over the fiscal year.
€ 455,154
▼ 74% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 4.5 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 16,330
▼ 72% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2 million
▲ 73% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 42 days on average.
€ 8,317
▲ € 7,117 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 18,437,763 | € 15,907,796 | € 18,306,608 | € 18,186,018 | ▼ 1% |
| Profit after taxes | € 56,852 | € 232,973 | € 921,276 | € 503,893 | ▼ 45% |
| Equity | € 4,960,738 | € 5,193,711 | € 6,114,986 | € 1,231,195 | ▼ 80% |
| Total debts | € 2,199,722 | € 1,514,764 | € 1,305,081 | € 2,044,227 | ▲ 57% |
| Cash | € 1,252,098 | € 1,425,156 | € 1,761,924 | € 455,154 | ▼ 74% |
| Land & buildings | € 1,166,331 | € 1,100,648 | € 808,820 | - | |
| Retained profit | € 4,942,188 | € 5,175,161 | € 6,096,436 | € 1,221,414 | ▼ 80% |
| Dividend | € 0 | € 0 | € 0 | € 4,500,000 | |
| Bank debt | € 361,695 | € 237,699 | € 124,036 | € 0 | ▼ 100% |
| Balance sheet total | € 7,160,460 | € 6,708,475 | € 7,420,068 | € 3,275,421 | ▼ 56% |
Key figures of PharmaCross, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PharmaCross?
What happened at PharmaCross in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 503,893 (▼ 45% vs 2024). filed late Source: NBB ↗
- New establishment in Deinze. KBO
- Start of the company according to the CBE. KBO
- Danny Vander Cruyssen became a director. NBB
In short
From € 56,852 profit in 2022 to € 503,893 profit in 2025.
Paid € 710,296 in corporate taxes since 2022.
Best year ever: 2024, with € 921,276 profit.
Paid out € 4.5 million in dividends to the owners in total.
A new publication or filing at PharmaCross? We notify you, reason included.
Follow PharmaCrossDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PharmaCross is Danny Vander Cruyssen. It owns 1% of Euro-Medic itself.
Directors
According to the 2025 annual accounts
since 2007
Establishments
Establishment units
Physical locations of this company
Poeldendries 49
9850 Deinze
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0888.580.475
- VAT number
- BE 0888.580.475
- Registered office
- Poeldendries 49, 9850 Deinze
- Names & denominations
- PharmaCross
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 April 2007
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten